FIB-4 Index
iatroX editorial team · Updated · Record checked · editorial policy
FIB-4 is a simple non-invasive index for liver fibrosis risk stratification calculated from age, AST, ALT, and platelet count. Formula: (Age × AST) / (Platelets × √ALT). It is widely used as a first-line triage tool for identifying patients who may have advanced hepatic fibrosis.
inputs
evidence
derivation
Originally developed by Sterling et al. (2006) in HIV-HCV co-infected patients as a simple fibrosis marker. Subsequently validated across multiple liver disease aetiologies.
validation
AUROC for advanced fibrosis (F3–F4) is approximately 0.80–0.85 across NAFLD, HCV, and ALD populations. The low cut-off (<1.30) has a negative predictive value exceeding 90% for excluding advanced fibrosis. The NICE NAFLD pathway recommends FIB-4 as the primary triage test.
guideline endorsements
NICE NG49 (Non-alcoholic fatty liver disease): FIB-4 as first-line assessment. EASL NAFLD/MASLD guidelines (2024): FIB-4 or NFS as initial non-invasive test. AASLD NAFLD guidance recommends FIB-4 for fibrosis risk stratification.
references
- Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325.PMID: 16729309
- Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-1112.PMID: 19523535
- NICE Guideline NG49. Non-alcoholic fatty liver disease (NAFLD): assessment and management. 2016.link ↗